Enterprise Value

193.7M

Cash

341.3M

Avg Qtr Burn

N/A

Short % of Float

21.79%

Insider Ownership

4.02%

Institutional Own.

33.89%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
OMIDRIA (phenylephrine and ketorolac intraocular solution) Details
Cataract surgery or intraocular lens replacement

Approved

Quarterly sales

Phase 3

Data readout

Phase 3

Data readout

Phase 2

Data readout

OMS1029 (MASP-2) Details
Lectin pathway disorder

Phase 2

Data readout

OMS527 (PDE7 inhibitor) Details
Movement disorder, Levodopa-induced dyskinesia associated with Parkinson’s disease, Cocaine use disorder, Addiction

Phase 2

Update

OMS906 Details
Paroxysmal nocturnal hemoglobinuria , Blood disorder

Phase 1b

Data readout

Narsoplimab (MASP-2 inhibitor, lectin pathway) Details
Kidney disease, Diabetic macular edema, Diabetes

Failed

Discontinued

Failed

Discontinued